18/11/2021 (Agence Europe) – The European Medicines Agency (EMA) announced on Thursday 18 November that it had started to evaluate an application made for marketing authorisation for the Covid-19 treatment candidate Xevudy (sotrovimab), developed by the British company GSK in collaboration with the American company Vir biotechnology. This monoclonal antibody is intended for the treatment of adults and adolescents who do not require supplemental oxygen therapy, but are at an increased risk...